{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T-Vec", "query": { "intervention": "T-Vec" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 46, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T-Vec&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T21:47:34.817Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03554044", "title": "T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Estrogen Receptor Positive", "HER2/Neu Negative", "Invasive Breast Carcinoma", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Recurrent Breast Carcinoma" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Talimogene Laherparepvec", "type": "BIOLOGICAL" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Nab paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2020-02-05", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2025-05-21", "last_synced_at": "2026-09-02T21:47:34.817Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03554044" }, { "nct_id": "NCT03300544", "title": "Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Rectal Adenocarcinoma", "Metastatic Rectal Adenocarcinoma", "Rectal Adenocarcinoma", "Stage III Rectal Cancer AJCC v7", "Stage IIIA Rectal Cancer AJCC v7", "Stage IIIB Rectal Cancer AJCC v7", "Stage IIIC Rectal Cancer AJCC v7", "Stage IV Rectal Cancer AJCC v7", "Stage IVA Rectal Cancer AJCC v7", "Stage IVB Rectal Cancer AJCC v7" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Talimogene Laherparepvec", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2019-05-14", "completion_date": "2022-03-22", "has_results": true, "last_update_posted_date": "2024-05-23", "last_synced_at": "2026-09-02T21:47:34.817Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03300544" }, { "nct_id": "NCT03069378", "title": "A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoma", "Epithelioid Sarcoma", "Cutaneous Angiosarcoma" ], "interventions": [ { "name": "Talimogene Laherparepvec (T-VEC)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2017-03-03", "completion_date": "2027-03", "has_results": true, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-09-02T21:47:34.817Z", "location_count": 5, "location_summary": "Menlo Park, California • Stanford, California • Harrison, New York + 2 more", "locations": [ { "city": "Menlo Park", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03069378" }, { "nct_id": "NCT02014441", "title": "Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Talimogene laherparepvec", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 61, "start_date": "2014-04-07", "completion_date": "2018-04-19", "has_results": true, "last_update_posted_date": "2019-11-20", "last_synced_at": "2026-09-02T21:47:34.817Z", "location_count": 11, "location_summary": "Tampa, Florida • Indianapolis, Indiana • Louisville, Kentucky + 8 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Fridley", "state": "Minnesota" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02014441" }, { "nct_id": "NCT02509507", "title": "Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma", "Liver Metastases", "Cutaneous or Subcutaneous Lymph Node", "Liver Tumors" ], "interventions": [ { "name": "Talimogene Laherparepvec", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2016-02-05", "completion_date": "2023-07-11", "has_results": true, "last_update_posted_date": "2024-08-06", "last_synced_at": "2026-09-02T21:47:34.817Z", "location_count": 9, "location_summary": "Scottsdale, Arizona • Santa Monica, California • Washington D.C., District of Columbia + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02509507" }, { "nct_id": "NCT00769704", "title": "Efficacy and Safety Study of Talimogene Laherparepvec Compared to Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Talimogene laherparepvec", "type": "BIOLOGICAL" }, { "name": "GM-CSF", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BioVex Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 437, "start_date": "2009-04", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2016-07-13", "last_synced_at": "2026-09-02T21:47:34.817Z", "location_count": 57, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00769704" }, { "nct_id": "NCT02890368", "title": "Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Mycosis Fungoides", "Melanoma", "Merkel-cell Carcinoma", "Squamous Cell Carcinoma", "Breast Carcinoma", "Human Papillomavirus-Related Malignant Neoplasm", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "TTI-621 Monotherapy", "type": "DRUG" }, { "name": "TTI-621 + PD-1/PD-L1 Inhibitor", "type": "DRUG" }, { "name": "TTI-621 + pegylated interferon-α2a", "type": "DRUG" }, { "name": "TTI-621 + T-Vec", "type": "OTHER" }, { "name": "TTI-621 + radiation", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2016-09", "completion_date": "2020-03-31", "has_results": false, "last_update_posted_date": "2023-04-05", "last_synced_at": "2026-09-02T21:47:34.817Z", "location_count": 7, "location_summary": "Duarte, California • New York, New York • Portland, Oregon + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Portland", "state": "Oregon" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02890368" }, { "nct_id": "NCT07102394", "title": "Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "NF1", "Neurofibromatosis", "Cutaneous Neurofibroma", "Neurofibroma", "Von Recklinghausen Disease", "Neurofibromas" ], "interventions": [ { "name": "Imlygic", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2026-02-01", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-09-02T21:47:34.817Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT07102394" }, { "nct_id": "NCT04068181", "title": "Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Talimogene laherparepvec", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 72, "start_date": "2020-01-22", "completion_date": "2024-02-26", "has_results": true, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-09-02T21:47:34.817Z", "location_count": 10, "location_summary": "Santa Barbara, California • Newark, Delaware • Orlando, Florida + 7 more", "locations": [ { "city": "Santa Barbara", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Orlando", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Fridley", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04068181" }, { "nct_id": "NCT03663712", "title": "Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Peritoneal Surface Malignancy" ], "interventions": [ { "name": "Talimogene Laherparepvec", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Dan Blazer III, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 28, "start_date": "2019-05-23", "completion_date": "2022-10-13", "has_results": true, "last_update_posted_date": "2024-11-20", "last_synced_at": "2026-09-02T21:47:34.817Z", "location_count": 3, "location_summary": "Chicago, Illinois • Durham, North Carolina • Winston-Salem, North Carolina", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03663712" } ] }